Associations - Cholangiocarcinoma

CANCER:

Cholangiocarcinoma

Related cancers:

‹

Biliary Tract Cancer (209)

Gallbladder Cancer (33)

Biliary Tract Cancer (209)

Gallbladder Cancer (33)

›

IDH1 mutation IDH1 mutation	Cholangiocarcinoma Cholangiocarcinoma	ivosidenib Sensitive: A2 - Guideline Servier Press Release - 5 days ivosidenib Sensitive : A2 Servier Press Release - 5d
dMMR/MSI-H + TMB-L dMMR/MSI-H + TMB-L	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 1 week PD1 inhibitor Resistant : C3 Clin Cancer Res - 1wk
PTEN mutation + MSI-H/dMMR PTEN mutation + MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 1 week PD1 inhibitor Resistant : C3 Clin Cancer Res - 1wk
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker No biomarker	Cholangiocarcinoma Cholangiocarcinoma	BGJ398 Sensitive: B - Late Trials BGJ398 Sensitive : B
FGFR2 rearrangement FGFR2 rearrangement	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	TAS 120 Sensitive: B - Late Trials TAS 120 Sensitive : B
HER-2 expression HER-2 expression	Cholangiocarcinoma Cholangiocarcinoma	trastuzumab + lapatinib Sensitive: B - Late Trials trastuzumab + lapatinib Sensitive : B
RET fusion RET fusion	Cholangiocarcinoma Cholangiocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
BRCA2 mutation BRCA2 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation FGFR2 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
BRAF V600 BRAF V600	Cholangiocarcinoma Cholangiocarcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
MSI-H/dMMR MSI-H/dMMR	Cholangiocarcinoma Cholangiocarcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
BRAF V600E BRAF V600E	Cholangiocarcinoma Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
NTRK2 fusion NTRK2 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion NTRK3 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK1 fusion NTRK1 fusion	Cholangiocarcinoma Cholangiocarcinoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
FGFR2 fusion FGFR2 fusion	Cholangiocarcinoma Cholangiocarcinoma	BGJ398 Sensitive: C2 – Inclusion Criteria BGJ398 Sensitive : C2
FGFR2 translocation FGFR2 translocation	Cholangiocarcinoma Cholangiocarcinoma	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES